Your browser doesn't support javascript.
loading
Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022.
Diallo, Alpha Oumar; Wikswo, Mary E; Sulemana, Iddrisu; Sahni, Leila C; Boom, Julie A; Ramani, Sasirekha; Selvarangan, Rangaraj; Moffatt, Mary E; Harrison, Christopher J; Halasa, Natasha; Chappell, James; Stewart, Laura; Staat, Mary Allen; Schlaudecker, Elizabeth; Quigley, Christina; Klein, Eileen J; Englund, Janet A; Zerr, Danielle M; Weinberg, Geoffrey A; Szilagyi, Peter G; Albertin, Christina; Johnston, Samantha H; Williams, John V; Michaels, Marian G; Hickey, Robert W; Curns, Aaron T; Honeywood, Michelle; Mijatovic-Rustempasic, Slavica; Esona, Mathew D; Bowen, Michael D; Parashar, Umesh D; Gautam, Rashi; Mirza, Sara A; Tate, Jacqueline E.
Afiliación
  • Diallo AO; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Wikswo ME; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Sulemana I; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Sahni LC; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Boom JA; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas.
  • Ramani S; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas.
  • Selvarangan R; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas.
  • Moffatt ME; Division of Infectious Diseases, Children's Mercy, Kansas City, Missouri.
  • Harrison CJ; Division of Infectious Diseases, Children's Mercy, Kansas City, Missouri.
  • Halasa N; Division of Infectious Diseases, Children's Mercy, Kansas City, Missouri.
  • Chappell J; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Stewart L; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Staat MA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Schlaudecker E; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Quigley C; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Klein EJ; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Englund JA; Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington.
  • Zerr DM; Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington.
  • Weinberg GA; Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington.
  • Szilagyi PG; University of Rochester School of Medicine and Dentistry and UR-Golisano Children's Hospital, Rochester.
  • Albertin C; University of Rochester School of Medicine and Dentistry and UR-Golisano Children's Hospital, Rochester.
  • Johnston SH; University of Rochester School of Medicine and Dentistry and UR-Golisano Children's Hospital, Rochester.
  • Williams JV; Department of Pediatrics, University of California at San Francisco, Benioff Children's Hospital Oakland, Oakland, California.
  • Michaels MG; Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Hickey RW; Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Curns AT; Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Honeywood M; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Mijatovic-Rustempasic S; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Esona MD; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Bowen MD; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Parashar UD; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Gautam R; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Mirza SA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Tate JE; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Pediatrics ; 154(4)2024 Oct 01.
Article en En | MEDLINE | ID: mdl-39252660
ABSTRACT

BACKGROUND:

Rotavirus was the leading cause of acute gastroenteritis among US children until vaccine introduction in 2006, after which, substantial declines in severe rotavirus disease occurred. We evaluated rotavirus vaccine effectiveness (VE) over 13 years (2009-2022).

METHODS:

We analyzed data from the New Vaccine Surveillance Network using a test-negative case-control design to estimate rotavirus VE against laboratory-confirmed rotavirus infections among children seeking care for acute gastroenteritis (≥3 diarrhea or ≥1 vomiting episodes within 24 hours) in the emergency department (ED) or hospital. Case-patients and control-patients were children whose stool specimens tested rotavirus positive or negative, respectively, by enzyme immunoassay or polymerase chain reaction assays. VE was calculated as (1-adjusted odds ratio)×100%. Adjusted odds ratios were calculated by multivariable unconditional logistic regression.

RESULTS:

Among 16 188 enrolled children age 8 to 59 months, 1720 (11%) tested positive for rotavirus. Case-patients were less often vaccinated against rotavirus than control-patients (62% versus 88%). VE for receiving ≥1 dose against rotavirus-associated ED visits or hospitalization was 78% (95% confidence interval [CI] 75%-80%). Stratifying by a modified Vesikari Severity Score, VE was 59% (95% CI 49%-67%), 80% (95% CI 77%-83%), and 94% (95% CI 90%-97%) against mild, moderately severe, and very severe disease, respectively. Rotavirus vaccines conferred protection against common circulating genotypes (G1P[8], G2P[4], G3P[8], G9P[8], and G12[P8]). VE was higher in children <3 years (73% to 88%); protection decreased as age increased.

CONCLUSIONS:

Rotavirus vaccines remain highly effective in preventing ED visits and hospitalizations in US children.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Rotavirus / Vacunas contra Rotavirus / Gastroenteritis / Eficacia de las Vacunas Límite: Child, preschool / Female / Humans / Infant / Male País/Región como asunto: America do norte Idioma: En Revista: Pediatrics Año: 2024 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Rotavirus / Vacunas contra Rotavirus / Gastroenteritis / Eficacia de las Vacunas Límite: Child, preschool / Female / Humans / Infant / Male País/Región como asunto: America do norte Idioma: En Revista: Pediatrics Año: 2024 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos